Studies which patient factors predict weight loss after endoscopic sleeve gastroplasty
Studies adults with obesity who had endoscopic sleeve gastroplasty, checking blood, stool and saliva samples.
Plain-language title generated from the registry record
Registry title: Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Hôpital Antoine BéclèreParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06153056
- Record updated
- 21 January 2026
- Original description
Endoscopic sleeve gastroplasty and bypass are currently available for weight loss in obese patients who have failed nutritional management. Despite very low risks, these techniques remain invasive. What's more, the French National Authority for Health recommends this procedure for patients with a BMI above 35 kg/m² with associated co-morbidities, or above 40 kg/m². This excludes grade I obese patients (30 < BMI < 35) who have no effective means of losing weight. The hospital's hepato-gastroenterology and nutrition department has therefore implemented endoscopic sleeve gastroplasty to address this problem. As with other surgical techniques, there is heterogeneity heterogeneity in weight loss. The investigators therefore aim to identify factors predictive of the efficacy of this procedure in order to improve patient management of patients.Read full original descriptionShow less
Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty & Study the Evolution of Clinical, Biological and Intestinal Intestinal Microbiota After Surgery
Endoscopic sleeve gastroplasty and bypass are currently available for weight loss in obese patients who have failed nutritional management. Despite very low risks, these techniques remain invasive. What's more, the French National Authority for Health recommends this procedure for patients with a BMI above 35 kg/m² with associated co-morbidities, or above 40 kg/m². This excludes grade I obese patients (30 < BMI < 35) who have no effective means of losing weight. The hospital's hepato-gastroenterology and nutrition department has therefore implemented endoscopic sleeve gastroplasty to address this problem. As with other surgical techniques, there is heterogeneity heterogeneity in weight loss. The investigators therefore aim to identify factors predictive of the efficacy of this procedure in order to improve patient management of patients.
Inclusion: Patient of legal age (Age ≥ 18 years); Patient capable of understanding the study and signing a consent; BMI between 30 and 35 kg/m² with the presence of at least one one obesity-related complication (diabetes, dyslipidemia, sleep apnea syndrome, non-alcoholic steatohepatitis, joint pain joint pain); Patients with a BMI greater than 35 kg/m² who have been bariatric surgery has been refused; Patient who has failed to lose weight and improve with conventional techniques; Patient affiliated to a social security scheme.
Exclusion: Patient having taken antibiotics 3 months prior to inclusion; Patient at risk of gastric cancer requiring regular endoscopic surveillance: extensive intestinal atrophy and/or metaplasia on biopsy; Patient with a history of gastrointestinal inflammatory disease of gastric localization, hepatic or renal insufficiency, portal hypertension; Patient with evidence of peptic ulcer disease and/or progressive peptic ulcer disease; Patient with a history of bariatric surgery; Patient under legal protection; Patient with pathology affecting general health health and/or life expectancy; Patient on AME.